You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)遭主要股東折讓6.5%減持八千萬股上板 股價續跌近4%
藥明生物(02269.HK)遭主要股東折讓6.5%減持8,000萬股(市前已上板),該股承過去兩連跌勢,今早進一步失守10天及20天線(135.7元及137.4),最低見131.8元,現造132.7元,續跌3.8%,為最弱藍籌,成交增至9,640萬股,涉資125億元。

藥明生物公布,獲主要股東Biologics知會,擬以每股129元(較昨天收市價折讓6.5%)配售8,000萬股,套現103.2億元。完成後,其持股量將由17.22%減至15.34%,仍為公司主要股東。

恆指逆歐美及區內股市連跌第三天,今早在比亞迪(01211.HK)、阿里(09988.HK)、舜宇(02382.HK)和申洲(02313.HK)高開逾1%-2%支撐,高開79點或0.3%報27,339,最多回升112點高見27,371無以為繼,在重磅新經濟股騰訊(00700.HK)、美團(03690.HK)及金融股疲弱拖累,掉頭重失牛熊線(27,177),最低見27,073,現造27,077,倒跌181點或近0.7%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account